Projects
Drug responses in breast cancer
The main goal of this project is to identify gene profiles that predict responses to hormonal therapies in breast cancer. Breast cancer is by far the most frequently occurring cancer in women worldwide, with approximately one million new cases annually. Scientists at Erasmus MC and the Netherlands Cancer Institute have developed the world’s first clinically useful DNA microarray tests for breast cancer. Agendia, a Dutch microarray diagnostic company, has developed one of these tests into the first commercially available microarray-based diagnostic test for breast cancer prognosis: MammaPrint. These three parties will now work together to develop microarray tests to predict which patients will respond to various types of hormonal therapy in breast cancer.
Partners: Agendia BV, Erasmus MC (University Medical Center Rotterdam), and Netherlands Cancer Institute
Full project title: Predicting drug responses in breast cancer
Relevant links:
Predicting Drug responses in breast cancer: Berns, Simon and van 't Veer